Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy with dismal outcomes for which no standard therapy exists. We found that primary BPDCN cells were dependent on the anti-apoptotic protein BCL-2 and were uniformly sensitive to the BCL-2 inhibitor venetoclax, as measured by direct cytotoxicity, apoptosis assays, and dynamic BH3 profiling. Animals bearing BPDCN patient-derived xenografts had disease responses and improved survival after venetoclax treatment in vivo. Finally, we report on two patients with relapsed/refractory BPDCN who received venetoclax off-label and experienced significant disease responses. We propose that venetoclax or other BCL-2 inhibitors undergo expedited clinical evaluation in BPDCN, alone or in combination with other therapies. In addition, these data illustrate an example of precision medicine to predict treatment response using ex vivo functional assessment of primary tumor tissue, without requiring a genetic biomarker.
Introduction
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy that presents with skin nodules and tumors, lymph node and splenic enlargement, central nervous system involvement, circulating leukemia, and/or bone marrow infiltration (1) . There is no standard therapy and patients empirically receive chemotherapy regimens based on retrospective case series (2) . For patients who respond to chemotherapy, autologous or allogeneic stem cell transplantation may prolong survival (3) . However, median survival is only approximately one year, or even shorter in patients who have disseminated disease (1, 2) . BPDCN has had many prior names, including CD4+CD56+ hematodermic neoplasm, blastic natural killer cell lymphoma, and agranular CD4+ natural killer cell leukemia, which has complicated study of the disease (1) . In 2008, BPDCN was recognized as the malignant counterpart of plasmacytoid dendritic cells (pDCs) (4) . However, the pathogenesis underlying the transformation of hematopoietic progenitors to BPDCN remains unclear. Targeted sequencing identified mutated genes in BPDCN that overlap with those observed in other hematologic malignancies, particularly myeloid diseases, including TET2, TP53, ASXL1, and RNA splicing factors (5, 6) . However, no BPDCN-specific mutations or immediately targetable alterations have been reported from those studies.
A gene expression analysis suggested that BPDCN was similar to acute myeloid leukemia (AML), and identified the anti-apoptotic gene BCL2 as more highly expressed in BPDCN compared to normal pDCs (7) . BCL2 is also expressed in AML and some AMLs are sensitive to the BCL-2 inhibitor venetoclax (8) . Venetoclax has a favorable safety profile and was recently approved by the US Food and Drug Administration (FDA) for use in patients with relapsed chronic lymphocytic leukemia (CLL) (9) . Here we demonstrate that BPDCN is dependent on BCL-2, and that venetoclax is active in BPDCN including in two patients with relapsed/refractory disease. Thus, BCL-2 inhibition could provide a novel therapeutic strategy in this chemotherapyresistant disease.
Results
We performed immunohistochemistry on BPDCN biopsies from bone marrow or skin, and in all cases we observed prominent BCL-2 staining compared to surrounding normal tissue ( Figure   1A , Supplementary Figure 1) . We saw similar BCL-2 expression in AML blasts from bone marrow and leukemia cutis (Supplementary Figure 1) . These data suggested that, like AML, BPDCN might have some degree of BCL-2 dependence. However, cell death in response to BCL-2 inhibition depends on a complex balance of pro-and anti-apoptotic factors, which makes sensitivity prediction challenging based on expression alone (10) .
Therefore, we performed functional mitochondrial profiling and conventional cytotoxicity assays to test BCL-2 inhibition in BPDCN. We first compared a BPDCN cell line, CAL1 (11) , to a series of AML cell lines that have a range of sensitivity to BCL-2 inhibition (12). CAL1 cells expressed similar levels of BCL-2 protein to the highest BCL-2 expressing AML cells ( Figure 1B ), but there was variability in the abundance of other apoptotic pathway proteins. To assess the functional dependence of these cell lines on specific BCL-2 family members, we performed BH3 profiling.
This technique exposes mitochondria to peptides that mimic the BH3 domain of pro-apoptotic BCL-2 family members and measures the induced change in mitochondrial permeability, the "point of no return" for apoptotic cell death (13) .
We determined the propensity of each cell line to initiate mitochondrial apoptosis after stimulation with a non-specific pro-death BIM peptide (overall priming), and the relative dependency on three anti-apoptotic BCL-2 family members: BCL-2, BCL-XL, and MCL-1. CAL1 cells were most dependent on BCL-2, as they showed significant priming in response to BAD stimulation (BCL-2/BCL-XL), but only minor priming after HRK (BCL-XL only) and none after MS1 (MCL-1) stimulation ( Figure 1C ). In contrast, AML cells were equally or less BCL-2 dependent, and/or were co-dependent on BCL-XL or MCL-1 in addition to BCL-2.
To directly measure responses to pharmacologic BCL-2 inhibition, we treated cells with venetoclax, a BH3 mimetic molecule that displaces pro-apoptotic proteins such as BIM from sequestration by BCL-2, allowing them to initiate mitochondrial permeabilization (14) . We performed dynamic BH3 profiling (15) , which measures the increase in apoptotic priming induced by incubation with a drug. Dynamic BH3 profiling strongly correlates with eventual induction of apoptotic cell death by the same treatment yet requires only short-term exposure to drug (<4 hours), which is advantageous in analyses of primary cells. By measuring the dosedependent cytochrome c release induced by BIM peptide we calculated the change in overall apoptotic priming caused by venetoclax pretreatment ("delta priming"). CAL1 cells had an equal or higher delta priming compared with the AML cells tested ( Figure 1D ).
As predicted by this result, CAL1 cells were equally or more sensitive to venetoclax compared with AML cells in viability assays ( Figure 1E ). We confirmed that venetoclax induces dosedependent apoptotic cell death in CAL1 cells by measuring Annexin V and propidium iodide staining following treatment ( Supplementary Figure 2A-B) . We also noted that dynamic BH3 profiling significantly correlated with Annexin V positivity in response to venetoclax (P=0.0067, Figure 1F ), supporting the validity of this assay as a functional surrogate of drug sensitivity. The predictions made by BH3 profiling across all cell lines were also confirmed using navitoclax (ABT-263), which inhibits both BCL-2 and BCL-XL, and A-1331852, which targets BCL-XL only (16) (Supplementary Figure 3) . Together, these data suggest that BPDCN cells are sensitive to venetoclax, at least in part because they are highly dependent on BCL-2 to inhibit mitochondrial apoptosis.
To test this hypothesis in primary cells, we analyzed patient bone marrow aspirates and skin biopsies involved by BPDCN, as well as BPDCN patient-derived xenografts (PDXs) (17) . PDXs displayed pathological characteristics of human BPDCN, including infiltration of bone marrow and spleen by CD4+CD56+CD123+ leukemia cells that were also BCL-2 positive (Supplementary Figure 4) . Patient tumor samples and PDXs were subjected to targeted DNA sequencing and represent a variety of genotypes (Supplementary Table 1 ).
Culturing primary leukemia cells in vitro to perform drug treatment assays is challenging. Ex vivo cytotoxicity assays with primary BPDCNs suggested a dose-dependent response to venetoclax in some cases (Supplementary Figure 5A-B) , but maintaining viability even in vehicle-treated samples for more than 8 hours was not uniformly feasible. Therefore, we performed BH3 profiling in primary BPDCNs similarly to how we had done in cell lines. In addition, we used flow cytometry-based BH3 profiling to measure cytochrome c release in defined subpopulations of interest (18) . Using this technique, we were able to selectively assess responses in leukemia cells admixed with normal cells. For comparison, we also tested a randomly selected set of primary AMLs. Baseline BCL-2/BCL-XL dependency was higher in BPDCN compared to AML (69.1% vs 2.1% priming by BAD peptide, P<0.0001 by t-test; Figure 2A) . Similarly, when permeabilized cells were directly stimulated with equivalent doses of venetoclax, BPDCNs had a higher level of cytochrome c release than the AMLs tested (57.4% vs 2.62%, P=0.0001; Figure 2B ).
Next, we used dynamic BH3 profiling to measure the change in apoptotic priming in response to venetoclax treatment of live cells with intact membranes. All BPDCNs had a significant increase in priming, or a decrease in their apoptotic threshold, after short-term treatment with venetoclax, and BPDCN priming was higher than in AML (59.8% vs 12.1%, P<0.0001; Figure 2C ). Normal bone marrow had significantly less priming than BPDCN in response to the same dose of venetoclax (18.5% vs 59.8%, P=0.0002; Figure 2C ), suggesting a therapeutic window.
We performed an orthogonal assay for apoptotic cell death by measuring cell surface Annexin V in primary BPDCN and AML after short-term venetoclax treatment. On average, BPDCN had a greater increase in Annexin V positivity than AML (2.25-fold vs 1.2-fold, P=0.03; Figure 2D ).
Annexin V positivity was significantly correlated with the increase in priming measured by dynamic BH3 profiling (P=0.0088, Figure 2D ). Together, these data suggest that BPDCN is highly BCL-2 dependent and predicts that BPDCN may be sensitive to venetoclax therapy.
To test BPDCN response to BCL-2 inhibition in vivo we transplanted two PDXs into recipient animals. When human BPDCN was detectable in blood, we randomized animals to treatment with venetoclax or vehicle for 28 days. After 21 days we sacrificed a subset for 
Discussion
We have demonstrated that BPDCN is dependent on BCL-2 and is markedly sensitive to BCL-2 inhibition with venetoclax. Amongst the primary leukemias, PDXs, and cell lines we tested, BPDCN was at least as sensitive to BCL-2 inhibition compared with AML. The BPDCN response to venetoclax compares favorably with CLL, a disease that has shown remarkable single agent activity, including in relapsed patients with unfavorable genetics (9) . BCL-2 inhibition should be formally evaluated in BPDCN as soon as possible, because there are few therapeutic options for these patients.
The mechanisms underlying BCL-2 dependence in BPDCN are unclear. There are no recurrent DNA copy number changes nor rearrangements reported involving the BCL2 locus (19, 20) , although additional analysis of BPDCN genomics may provide more insight into its BCL-2 dependency. Prior studies in AML have suggested that specific somatic mutations may be enriched in venetoclax-sensitive leukemias (8, 21) . Larger numbers of BPDCN patients treated with venetoclax with complete genetic annotation will be required to make definitive genotypephenotype correlations in this disease. However, we note that the primary BPDCNs tested here harbored a variety of mutations in genes associated with hematologic malignancies (Supplementary Table 1) , and all responded to venetoclax by BH3 profiling. Normal pDCs are selectively depleted in vivo by venetoclax compared to conventional dendritic cells (cDCs) and other hematopoietic cell types (22) , suggesting that the sensitivity we observed could represent a lineage-specific dependency.
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Finally, these data demonstrate precision cancer therapy directed by functional rather than 
Patient samples
Primary BPDCN and AML cells were collected from patients who had consented to IRBapproved research protocols for sample analysis from patients with hematologic malignancies.
Bone marrow aspirate mononuclear cells from BPDCN and AML patients were purified by Ficoll density centrifugation using standard procedures. Skin biopsies were exposed to an enzymatic digestion solution in 2.5 mL of DMEM/F12 media containing 125 U DNAse I (Sigma Aldrich #DN25), 100 U hyaluronidase (Sigma Aldrich #H3506), and 300 U collagenase IV (Gibco #17104-019). The tissue suspension was processed using gentleMACS™ Dissociator (Miltenyl Biotec) using the hTUMOR 1 program. The suspension was then incubated at 37 o C for 30 min with constant agitation. Then, dissociation was repeated using the hTUMOR 1 program, and the 30 min incubation was repeated. We then filtered the suspension through a 70 micron filter and cells were centrifuged at 400 x g for 5 min. To lyse residual red blood cells, 100 μL of ice cold water was added to the pellet for 15 sec and then diluted to 50 mL with PBS. Then, cells were centrifuged and resuspended in RPMI media for subsequent analysis.
Antibodies and Western blotting
Samples for Western blotting were prepared by lysing Western blots were imaged using an ImageQuant LAS-4000 (GE Healthcare, #28-9558-10).
Drug treatment of cell lines
Cell lines cultured in RPMI-1640 with 10% FBS were plated in a 96-well dish at a concentration of 5000 cells per 120 µL media. Compounds were added to the cells in serial five-fold dilutions.
After a 72 hr incubation at 37°C, viability was determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. In brief, 40 µL of 5 mg/mL MTT (EMD Millipore, #475989) was added to each well and incubated for 2 hrs, and then 100 µL MTT lysis buffer was added to each well followed by additional 4 hr incubation. Absorbance values were measured using a SpectraMax M3 plate reader (Molecular Devices) at 570 and 630 nm.
Viability curves values were generated using the nonlinear regression (curve fit) function in GraphPad Prism (GraphPad Software, Inc.).
Annexin V flow cytometry
The cells were treated with drug for the indicated times, washed with Annexin V binding buffer (ABB) and stained with 1:100 dilutions of Annexin V-FITC (Biolegend, #640906), CD45-APC (BD Biosciences, #340943) and CD123-PerCP-Cy5.5 (BD Pharmingen, #560904) for 30 min.
Samples were the washed twice with ABB, propidium iodide (BD Pharmingen, #51-66211E) was added after the last wash, and then cells were analyzed using a Cytoflex flow cytometer (Beckman Coulter, #B53012).
BH3 profiling
Baseline and dynamic BH3 profiling were performed as described (13, 15) . Dynamic BH3 profiling was performed after 4 hrs of incubation of cell lines or primary leukemia cells in vehicle or 100 nM venetoclax, unless otherwise specified. We used a flow cytometry-based BH3
profiling to perform the analysis, as previously described (18), using Zombie Aqua Dye (Biolegend, #423101) for viability, CD123-PerCP-Cy5.5 (BD Pharmingen, #560904), CD56-PECy7 (BD Pharmingen, #557747), and cytochrome c-Alexa Fluor 647 (Biolegend, #612310).
Patient derived xenografts
All animal experiments were approved by Institutional Animal Care and Use Committees.
BPDCN PDXs were generated as described in the Dana-Farber Cancer Institute Public
Repository of Xenografts (PRoXe.org) (17) . were sacrificed at day 21 of treatment for pharmacodynamic assessment. The remaining animals were followed for survival. Both PDXs showed evidence of tumor response. PD and survival analysis for PDX4 is shown in Figure 3 , and PDX1 in Supplementary Figure 4 . KaplanMeier curves were compared using the log-rank test in GraphPad Prism. Immunohistochemistry was performed in the Dana-Farber/Harvard Cancer Center Specialized Histopathology Core Laboratory using standard protocols.
DNA sequencing
Patient samples were sequenced using a 95-gene targeted sequencing panel covering genes recurrently mutated in hematologic malignancies (25) .
Venetoclax treatment
Patients with relapsed/refractory BPDCN who had exhausted other treatment options were prescribed venetoclax off-label by their treating physicians after they signed written informed consent. Prescriptions were filled in standard outpatient pharmacies after the FDA approval of venetoclax in 2016. The patients provided written informed consent to IRB-approved protocols for sample collection from patients with hematologic malignancies. They also signed additional specific consents for photographic data to be published, and all studies were in accordance with the Declaration of Helsinki. Patient #1 received oral venetoclax with a weekly dose escalation, starting at 20 mg daily for 7 days, followed by 50 mg daily for 7 days, 100 mg daily for 7 days, 200 mg daily for 7 days, followed by 400 mg daily. He was admitted to the hospital for the first dose initiation and the escalation to 50 mg to monitor for tumor lysis syndrome. Patient #2
received oral venetoclax with a daily dose escalation of 50 mg for one day, 100 mg for one day, 200 mg for one day, and then 400 mg daily. He was admitted to the hospital during the dose escalation to monitor for tumor lysis. 
